Cardiff Lexington CORP (CDIX) — SEC Filings

Overview

Cardiff Lexington CORP (CDIX) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a S-1 filed on Dec 15, 2025: Cardiff Lexington Corporation (CDIX) is a targeted healthcare holding company focused on acquiring and building middle-market niche healthcare clinics, primarily in orthopedics, spine care, and pain management. The company's revenue is entirely derived from Nova Ortho and Spine, LLC, which generated

Sentiment Summary

Across 24 filings, the sentiment breakdown is: 3 bearish, 21 neutral. The dominant filing sentiment for Cardiff Lexington CORP is neutral.

Filing Type Overview

Cardiff Lexington CORP (CDIX) has filed 1 S-1, 5 10-Q, 3 10-K/A, 8 8-K, 2 10-K, 1 10-Q/A, 4 S-1/A with the SEC between Jan 2024 to Dec 2025.

Filings by Year

2025 · 2024

Recent Filings (24)

• Cardiff Lexington Posts $3.3M Loss, Seeks Nasdaq Uplisting Amid Revenue Swings — S-1 · Dec 15, 2025 Risk: high
  Cardiff Lexington Corporation (CDIX) is a targeted healthcare holding company focused on acquiring and building middle-market niche healthcare clinics, primaril
• CDIX Revenue Soars 70% But Mounting Debt Widens Net Loss — 10-Q · Nov 12, 2025 Risk: high
  Cardiff Lexington Corp (CDIX) reported a significant increase in revenue for the nine months ended September 30, 2025, reaching $8,763,314, up from $5,149,416 i
• Cardiff Lexington Corp Files 10-K/A Amendment — 10-K/A · Aug 19, 2025 Risk: low
  Cardiff Lexington Corporation filed an amendment (10-K/A) to its annual report on August 19, 2025, for the fiscal year ending December 31, 2024. The company, pr
• Cardiff Lexington Corp Restates Financials — 8-K · Aug 14, 2025 Risk: high
  Cardiff Lexington Corporation announced on August 14, 2025, that it will not rely on previously issued financial statements or related audit reports due to an o
• Cardiff Lexington Corp. Files Q1 2025 10-Q — 10-Q · May 9, 2025 Risk: low
  Cardiff Lexington Corp. filed its 10-Q for the period ending March 31, 2025. The company, formerly known as Cardiff International Inc., is based in Las Vegas, N
• Cardiff Lexington Corp Files 2024 10-K — 10-K · Mar 14, 2025 Risk: low
  Cardiff Lexington Corporation filed its 2024 10-K on March 14, 2025, reporting on its fiscal year ending December 31, 2024. The company, formerly known as Cardi
• Cardiff Lexington Corp Files 8-K on Security Holder Rights — 8-K · Dec 4, 2024 Risk: medium
  Cardiff Lexington Corporation filed an 8-K on December 4, 2024, reporting on events that occurred on November 27, 2024. The filing indicates material modificati
• Cardiff Lexington Corp. Files Q3 2024 10-Q — 10-Q · Nov 6, 2024 Risk: low
  Cardiff Lexington Corp. filed its 10-Q for the period ending September 30, 2024. The filing details the company's financial performance and position. Specific f
• Cardiff Lexington Corp Revises Q1 2024 Financials — 10-Q/A · Oct 17, 2024 Risk: medium
  Cardiff Lexington Corporation filed an amendment (10-Q/A) on October 17, 2024, to revise its financial statements for the period ending March 31, 2024. The fili
• Cardiff Lexington Corp Appoints New Auditor — 8-K · Sep 19, 2024 Risk: medium
  Cardiff Lexington Corporation announced on September 19, 2024, that it has appointed a new independent registered public accounting firm, effective September 13
• Cardiff Lexington Corp. Files Q2 2024 10-Q — 10-Q · Aug 14, 2024 Risk: low
  Cardiff Lexington Corp. filed its 10-Q for the period ending June 30, 2024. The company, formerly known as Cardiff International Inc., is incorporated in Florid
• Cardiff Lexington Corp. Amends 2023 10-K Filing — 10-K/A · Aug 8, 2024 Risk: low
  Cardiff Lexington Corp. filed Amendment #3 to its 2023 Form 10-K on August 8, 2024, to amend its financial statements for the fiscal year ending December 31, 20
• Cardiff Lexington Corp. Files 2023 Annual Report Amendment — 10-K/A · Jul 24, 2024 Risk: low
  Cardiff Lexington Corp. filed an amendment (10-K/A) to its annual report for the fiscal year ending December 31, 2023. The filing, dated July 24, 2024, provides
• Cardiff Lexington Corp Files S-1/A Amendment — S-1/A · Jun 18, 2024 Risk: medium
  Cardiff Lexington Corporation filed an S-1/A amendment on June 18, 2024, responding to SEC comments regarding its registration statement (No. 333-273324). The c
• Cardiff Lexington Corp. Files S-1/A Amendment — S-1/A · Jun 12, 2024 Risk: medium
  Cardiff Lexington Corp. filed an S-1/A amendment on June 12, 2024, responding to SEC comments. The company, formerly known as Cardiff International Inc., is inc
• Cardiff Lexington Corp Enters Material Definitive Agreement — 8-K · Jun 11, 2024 Risk: medium
  On June 11, 2024, Cardiff Lexington Corporation entered into a material definitive agreement. The filing also includes financial statements and exhibits related
• Cardiff Lexington Corp Appoints New CMO, Director — 8-K · Jun 10, 2024 Risk: medium
  Cardiff Lexington Corporation announced on June 5, 2024, the appointment of Dr. David L. Smith as Chief Medical Officer and the election of Mr. Robert L. Johnso
• Cardiff Lexington Corp. Files S-1/A Amendment — S-1/A · May 31, 2024 Risk: medium
  Cardiff Lexington Corp. filed an S-1/A amendment on May 31, 2024, responding to SEC comments. The filing details financial information for the period ending Mar
• Cardiff Lexington Corp Files 8-K with Material Agreements — 8-K · May 14, 2024 Risk: medium
  On May 13, 2024, Cardiff Lexington Corporation entered into a Material Definitive Agreement. The company also reported on unregistered sales of equity securitie
• Cardiff Lexington Corp Files 10-Q for Period Ending March 31, 2024 — 10-Q · May 10, 2024 Risk: low
  Cardiff Lexington Corp (CDIX) filed a Quarterly Report (10-Q) with the SEC on May 10, 2024. Cardiff Lexington Corporation filed a 10-Q report for the quarterly
• Cardiff Lexington Corp Files S-1/A Amendment — S-1/A · Apr 5, 2024 Risk: low
  Cardiff Lexington Corp (CDIX) filed a Amended IPO Registration (S-1/A) with the SEC on April 5, 2024. Cardiff Lexington Corporation filed an S-1/A amendment on
• Cardiff Lexington Corp Files 2023 Annual Report on Form 10-K — 10-K · Mar 27, 2024 Risk: low
  Cardiff Lexington Corp (CDIX) filed a Annual Report (10-K) with the SEC on March 27, 2024. Cardiff Lexington Corporation filed its 10-K report for the fiscal ye
• Cardiff Lexington Files 8-K on Shareholder Vote Submission — 8-K · Jan 31, 2024
  Cardiff Lexington Corp. filed an 8-K on January 31, 2024, indicating a 'Submission of Matters to a Vote of Security Holders.' This filing is a procedural update
• Cardiff Lexington 8-K: Leadership & Comp Changes Reported — 8-K · Jan 4, 2024
  Cardiff Lexington Corp filed an 8-K on January 4, 2024, reporting events that occurred on March 1, 2023. The filing indicates changes related to the departure o

Risk Profile

Risk Assessment: Of CDIX's 22 recent filings, 3 were flagged as high-risk, 9 as medium-risk, and 10 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.

Financial Highlights

Key financial metrics from Cardiff Lexington CORP's most recent 10-Q filing (Nov 12, 2025):

• Revenue: $8.76M
• Net Income: $(2.82M)
• EPS: $(0.20)
• Cash Position: $232K
• Total Assets: $27.61M
• Total Debt: $22.60M

Key Executives

• Alex Cunningham
• Dr. David L. Smith
• Mr. Robert L. Johnson

Industry Context

The healthcare services sector, particularly in specialized areas like orthopedics, spine care, and pain management, is characterized by an aging population and increasing demand for elective procedures. However, it is also subject to significant regulatory oversight, evolving reimbursement models, and intense competition from both independent providers and larger healthcare systems.

Top Tags

amendment (6) · 10-Q (5) · financials (4) · annual-report (3) · quarterly-report (3) · 10-K (3) · corporate-governance (3) · sec-filing (3) · Cardiff Lexington Corp (3) · Net Loss (2)

Key Numbers

• Revenue for year ended Dec 31, 2024: $8,270,126 — Decreased from $11,853,266 in 2023
• Revenue for year ended Dec 31, 2023: $11,853,266 — Higher than 2024 revenue
• Revenue for nine months ended Sep 30, 2025: $8,763,314 — Increased from $5,149,416 in the same period of 2024
• Net loss for year ended Dec 31, 2024: $3,302,999 — Significant swing from net income of $3,028,394 in 2023
• Net income for year ended Dec 31, 2023: $3,028,394 — Preceded the net loss in 2024
• Net loss for nine months ended Sep 30, 2025: $2,821,471 — Continued losses from $2,392,657 in the same period of 2024
• Closing price of common stock on Dec 12, 2025: $1.70 — Current trading price on OTCQB Market
• Underwriting discounts and commissions: 8% — Percentage of public offering price
• Non-accountable expense allowance: 1% — Payable to R.F. Lafferty & Co., Inc.
• Over-allotment option: 15% — Percentage of shares offered granted to underwriters
• Revenue: $8.76M — Increased 70.2% for the nine months ended September 30, 2025, from $5.15M in 2024.
• Net Loss: $(2.82M) — Widened from $(2.39M) in the prior year, primarily due to increased interest expense.
• Interest Expense: $4.59M — Increased significantly from $1.80M in the prior year, impacting profitability.
• Cash: $232K — Decreased sharply from $1.19M at December 31, 2024, indicating liquidity strain.
• Line of Credit: $14.73M — Increased from $8.65M at December 31, 2024, contributing to higher liabilities.

Related Companies

CDIF

Frequently Asked Questions